New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
10:15 EDTMYGNMyriad says trial date not scheduled after injunctive relief denied
Myriad Genetics confirmed earlier today that the U.S. District Court for the District of Utah denied its motion for preliminary injunctive relief. Myriad alleges that Ambry Genetics' testing services infringe various patent claims owned by the BRCA patent owners which relate to the BRCA1 and BRCA2 genes, and were seeking a preliminary injunction to prevent Ambry from selling the testing services. The company said, "We believe the BRCA patents at issue in this case are valid, enforceable and infringed, and are confident we will prevail based on the full evidence. A trial date has not been scheduled." Shares of Myriad are down 9%, or $3.58, to $34.17 in early trading.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
10:44 EDTMYGNCMS may have made mistake with Myriad BRCA pricing, says Piper Jaffray
Piper Jaffray analyst William Quirk noted that the Centers for Medicare and Medicaid Services, or CMS, released the final 2016 Clinical Diagnostic Laboratory Fee Schedule yesterday, which showed Myriad Genetics' BRCA1/2 sequencing and full duplication/deletion analysis priced at $1,839.54, down from the $2,483.37 listed in the preliminary and final CLFS determination documents. Quirk said this may be an error and that he anticipates CMS to issue a correction and/or Myriad to file an appeal in the near-term. The analyst keeps an Overweight rating on Myriad shares.
November 23, 2015
05:36 EDTMYGNGenomic Health upgraded to Buy from Neutral at UBS
Subscribe for More Information
November 19, 2015
07:19 EDTMYGNCMS decision a big positive for Myriad Genetics, says Stephens
Subscribe for More Information
November 18, 2015
09:49 EDTMYGNCMS reversal removes 'huge overhang' for CareDx, says Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use